Annexon Inc (ANNX) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
Annexon Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Annexon Inc 's ROA in the third quarter of 2026?
Annexon Inc recorded a cumulative net loss of $-199 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -76.83%.
However, within the Healthcare sector 684 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4192, from total ROA ranking in the second quarter of 2026 at 4898.
Annexon Expands Senior Leadership to Accelerate Global Neuroinflammatory-Targeted Portfolio In a move aimed at advancing its late-stage neuroinflammatory-targeted portfolio, Annexon, Inc. has bolstered its senior leadership team. The biopharmaceutical company, known for its novel complement therapies for diseases of the body, brain, and eye, announced the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial; Sunil B. Mehta, Pharm.D as senior vice president of medical affairs; and Myoung Kim, PHD, M.A. M.B.A. as vice president of health economics and outcomes research. The addition of these seasoned professionals to Annexon s leadership team is expected to bring substantial expertise and innovation to the company. Shikhar Agarwal, with his extensive experience in commercial strategy and operations, will play a pivotal role in driving the commercialization efforts of Annexon s groundbreaking neuroinflammatory therapies. Sunil B. Mehta s expertise in medical affairs will be instrumental in ensuring the safe and effective use of these therapies, as well as building strong relationships with healthcare professionals and regulatory bodies. Lastly, Myoung Kim, a distinguished health economist, will lead research efforts to demonstrate the value and long-term benefits of Annexon s treatments.
Annexon Presents Positive Phase 3 Results for ANX005 in Guillain-Barr Syndrome at PNS Annual Meeting Brisbane, Calif. – At the annual meeting of the Peripheral Nerve Society (PNS) in 2024, Annexon Inc., a clinical-stage biopharmaceutical company focusing on innovative complement medicines for classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, shared encouraging findings from the Phase 3 clinical trial of their C1q-targeted immunotherapy, ANX005, in patients with Guillain-Barr Syndrome. The results demonstrated that patients treated with ANX005 experienced faster and more complete recovery from week 1 through week 26, as observed across multiple pre-specified endpoints. Guillain-Barr Syndrome (GBS) is a rare neurological disorder where the body s immune system mistakenly attacks the peripheral nerves. Currently, there are limited treatment options available for GBS, emphasizing the significance of Annexon s findings.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
